On this page

Marico lifts PLIX stake to 84% with ₹1,012 crore deal; remaining 14% expected in July 2027

Marico acquired a further 24.09% of PLIX parent Satiya Nutraceuticals for ₹1,012.03 crore on October 5, lifting its holding to 84.09%. The remaining 14.09% is expected to be acquired in July 2027. Marico also expects to surpass near-term guidance.

Newer report on another story , , The Hindu BusinessLine : Marico's cheaper copra lifts margins, but 87% monsoon clouds FMCG's second-half outlook

Read next

  1. JPMorgan keeps Marico at overweight, Rs 915 target implies ~16% upside after Q2 update, , NDTV Profit
  2. Trent Q2 standalone revenue rises 23% YoY as Marico buys 60% of PLIX owner Satiya Nutraceuticals, , Business Standard

The numbers

Figures from CNBC-TV18,

Aggregate consideration for 84.09% stake: ₹1,392.07 crore
Base consideration for remaining stake: up to ₹592 crore
Stake held by founders and others: 38.18%

What to watch next

  • Marico quarterly results showing PLIX revenue growth and margin contribution
  • Any exchange filing that changes the ₹592 crore base consideration or the July 2027 timing
  • Management commentary on PLIX distribution expansion beyond D2C channels
  • Marico's July 2027 filing confirming completion of the remaining 14.09%
  • Fresh funding or acquisition activity among competing D2C nutrition brands

Likely next moves

Our read of what comes next — analysis, not reported by the source.

  • Marico is likely to consolidate Satiya Nutraceuticals at its 84.09% holding and report PLIX as a larger contributor to its growth and margin story in coming quarters.
  • Expect Marico to push PLIX through its wider distribution, including modern trade and quick-commerce, to show the ₹1,392 crore aggregate outlay is earning a return.
  • Marico is likely to describe the July 2027 purchase of the remaining 14.09% as a planned step and confirm it through a stock-exchange disclosure when it closes.
  • PLIX's remaining minority holders are likely to focus on growth targets that set the final consideration, up to ₹592 crore, and may lobby for the upper end of that range.
  • Rival D2C and plant-based nutrition brands may step up marketing and seek strategic capital, citing Marico's bigger commitment as validation of the category.

The source

Source Read the source at CNBC-TV18

Published

Also reported by Inc42, NDTV Profit, Storyboard18, Entrackr, afaqs, The Hindu BusinessLine, BW Disrupt

First seen